Dx&Vx signs 3 billion-won precision medical genome analysis contract


On the 30th, Dx&Vx announced that it has signed a 3 billion won ($2.38 million) contract with COREE to provide precision medical genome analysis service. This agreement is aimed at establishing big data for the health industry and new drug development.

Starting this year, the research project will turn at least 10,000 immunocyte profiling results into big data over three years. Ultimately, the end goal of this project is to analyze biological data related to infectious diseases and utilize them for diagnosis and development of customized immunotherapies.

COREE has also partnered with Beijing Union Hospital and Italy’s Gemelli Hospital to conduct clinical research into maternal and child health and chronic metabolic diseases. It is expected that these series of clinical studies will bring positive ripple effects.

Park Sang-tae, CEO of Dx&Vx, said, “Over the past year, we formed four cohort groups to conduct 3,156 immunocyte-profiled whole genome sequencing genes and immunocyte-related genomic analyses. The database will be used to develop biomarkers for customized immunotherapies based on the Oxford Vacmedix’s clinical trial of anticancer vaccines.”

Park added, “Through this two-tiered research, we plans to tremendously reinforce data on cell-free deoxyribonucleic acid (cfDNA) and ribonucleic acid (RNA), thus advancing the development of multi-omics biomarkers.”

Dx&Vx leads the Molecular Genetic Research Center and the Microbiome Research Center. Based on the multi-omics research conducted by the two research centers, various product pipelines in the field of diagnosis and microbiome are under development.